{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:58:55Z","timestamp":1761101935988},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,4,21]],"date-time":"2011-04-21T00:00:00Z","timestamp":1303344000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1007\/s12185-011-0837-4","type":"journal-article","created":{"date-parts":[[2011,4,20]],"date-time":"2011-04-20T02:21:28Z","timestamp":1303266088000},"page":"610-617","source":"Crossref","is-referenced-by-count":9,"title":["Homoharringtonine as a backbone drug for the treatment of newly diagnosed pediatric acute myeloid leukemia: a report from a single institution in China"],"prefix":"10.1007","volume":"93","author":[{"given":"JingYan","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiliang","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ci","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LongJun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,4,21]]},"reference":[{"key":"837_CR1","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1182\/blood-2007-04-084293","volume":"111","author":"BJ Lange","year":"2008","unstructured":"Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a children\u2019s oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the Children\u2019s Oncology Group. Blood. 2008;111:1044\u201353.","journal-title":"Blood"},{"key":"837_CR2","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1038\/sj.leu.2403873","volume":"19","author":"G Kardos","year":"2005","unstructured":"Kardos G, Zwaan CM, Kaspers GJL, et al. Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials. Leukemia. 2005;19:2063\u201371.","journal-title":"Leukemia"},{"issue":"1","key":"837_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/hon.744","volume":"23","author":"S Alvarez","year":"2005","unstructured":"Alvarez S, Cigudosa JC. Gains, losses and complex karyotypes in myeloid disorders: a light at the end of the tunnel. Hematol Oncol. 2005;23(1):18\u201325.","journal-title":"Hematol Oncol"},{"issue":"12","key":"837_CR4","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1038\/sj.leu.2403920","volume":"19","author":"U Creutzig","year":"2005","unstructured":"Creutzig U, Zimmermann M, Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia. 2005;19(12):2030\u201342.","journal-title":"Leukemia"},{"issue":"12","key":"837_CR5","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1038\/sj.leu.2403924","volume":"19","author":"BE Gibson","year":"2005","unstructured":"Gibson BE, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia. 2005;19(12):2130\u20138.","journal-title":"Leukemia"},{"issue":"12","key":"837_CR6","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1038\/sj.leu.2403867","volume":"19","author":"Y Perel","year":"2005","unstructured":"Perel Y, Auvrignon A, Leblanc T, et al. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit-multicenter studies of the French LAME (Leucemie Aigue Myeloblastique Enfant) Cooperative Group. Leukemia. 2005;19(12):2082\u20139.","journal-title":"Leukemia"},{"issue":"12","key":"837_CR7","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1038\/sj.leu.2403925","volume":"19","author":"FO Smith","year":"2005","unstructured":"Smith FO, Alonzo TA, Gerbing RB, et al. Children\u2019s Cancer Group. Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children\u2019s Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia. 2005;19(12):2054\u201362.","journal-title":"Leukemia"},{"issue":"12","key":"837_CR8","first-page":"987","volume":"82","author":"DC Zhou","year":"1995","unstructured":"Zhou DC, Zittoun R, Marie JP. Homoharringtonine: an effective new natural product in cancer chemotherapy. Bull Cancer. 1995;82(12):987\u201395.","journal-title":"Bull Cancer"},{"issue":"8","key":"837_CR9","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1038\/sj.leu.2404287","volume":"20","author":"J Jin","year":"2006","unstructured":"Jin J, Jiang DZ, Mai WY, et al. Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia. 2006;20(8):1361\u20137.","journal-title":"Leukemia"},{"issue":"3","key":"837_CR10","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1158\/1535-7163.MCT-05-0164","volume":"5","author":"R Tang","year":"2006","unstructured":"Tang R, Faussat AM, Majdak P, et al. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther. 2006;5(3):723\u201331.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"837_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/10245330410001714194","volume":"9","author":"CY Luo","year":"2004","unstructured":"Luo CY, Tang JY, Wang YP. Homoharringtonine: a new treatment option for myeloid leukemia. Hematology. 2004;9(4):259\u201370.","journal-title":"Hematology"},{"issue":"4","key":"837_CR12","first-page":"240","volume":"17","author":"Y Li","year":"1990","unstructured":"Li Y. Clinical evaluation on the therapeutic efficacy of HA and HHA on acute nonlymphocytic leukemia. Chin J Clin Oncol. 1990;17(4):240\u20133.","journal-title":"Chin J Clin Oncol"},{"issue":"5","key":"837_CR13","first-page":"319","volume":"6","author":"Shanghai Leukemia Research Cooperative Group","year":"1983","unstructured":"Shanghai Leukemia Research Cooperative Group. Clinical study of Cephalotaxin esters in the treatment of acute nonlymphocytic leukemia. Shanghai Med J. 1983;6(5):319\u201324.","journal-title":"Shanghai Med J"},{"issue":"3","key":"837_CR14","first-page":"162","volume":"17","author":"Fujian Province Leukemia Research Cooperative Group","year":"1978","unstructured":"Fujian Province Leukemia Research Cooperative Group. Homoharringtonine and harringtonine in acute nonlymphocytic leukemia: clinical observation of 40 cases. Chin J Intern Med. 1978;17(3):162\u20134.","journal-title":"Chin J Intern Med"},{"issue":"4","key":"837_CR15","first-page":"249","volume":"6","author":"J Lu","year":"1979","unstructured":"Lu J, Yan P, Ke C. A preliminary observation of the therapeutic effect of Cephalotaxine esters combined with traditional Chinese medicine in the treatment of 19 cases of Nonlymphocytic leukemia. Acta Acad Med Primae Shanghai. 1979;6(4):249\u201354.","journal-title":"Acta Acad Med Primae Shanghai"},{"issue":"4","key":"837_CR16","first-page":"205","volume":"20","author":"Hematological Research Section of Suzhou Medical Collage","year":"1981","unstructured":"Hematological Research Section of Suzhou Medical Collage. Analysis of 51 cases of acute nonlymphocytic leukemia treated with combined programme of Chinese traditional medical and HOAP. Chin J Intern Med. 1981;20(4):205\u20137.","journal-title":"Chin J Intern Med"},{"issue":"12","key":"837_CR17","first-page":"732","volume":"20","author":"L Lu","year":"1981","unstructured":"Lu L, Chen J, Liang Y. Clinical observation of the therapeutic effect in 19 cases of acute nonlymphocytic leukemia with combined Chinese traditional and western medicine. Chin J Intern Med. 1981;20(12):732\u20134.","journal-title":"Chin J Intern Med"},{"issue":"4","key":"837_CR18","first-page":"231","volume":"19","author":"Y Li","year":"1981","unstructured":"Li Y, Kuo S, Zhou F. A report of Cephalotaxine esters in the combined treatment in 25 cases of acute nonlymphocytic leukemia. Chin J Pediatr. 1981;19(4):231\u20133.","journal-title":"Chin J Pediatr"},{"issue":"3","key":"837_CR19","first-page":"184","volume":"12","author":"Hematological Group, Department of Internal Medicine, the Third Affiliated Hospital, Beijing Medical Collage","year":"1980","unstructured":"Hematological Group, Department of Internal Medicine, the Third Affiliated Hospital, Beijing Medical Collage. The \u201cHHOAP\u201d regimen in the treatment of acute nonlymphocytic leukemia. Clinical observation of 21 cases. J Beijing Med Collage 1980;12(3):184\u20136.","journal-title":"J Beijing Med Collage"},{"issue":"5","key":"837_CR20","first-page":"296","volume":"3","author":"Z Hua","year":"1982","unstructured":"Hua Z, Xiong S. Clinical traditional drugs to therapeutic effect of combined HOAP and Chinese traditional drugs to acute nonlymphocytic leukemia. Chin J Hematol. 1982;3(5):296\u20138.","journal-title":"Chin J Hematol"},{"issue":"8","key":"837_CR21","first-page":"499","volume":"9","author":"Low Dose Homoharringtonine Therapy East China Cooperative Group","year":"1988","unstructured":"Low Dose Homoharringtonine Therapy East China Cooperative Group. Preliminary observation of low dose homoharringtonine in treatment of acute nonlymphocytic leukemia in 48 cases. Chin J Hematol. 1988;9(8):499\u2013500.","journal-title":"Chin J Hematol"},{"issue":"5","key":"837_CR22","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/sj.leu.2400608","volume":"11","author":"G Visani","year":"1997","unstructured":"Visani G, Russo D, Ottaviani E, et al. Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on \u201cin vitro\u201d growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors. Leukemia. 1997;11(5):624\u20138.","journal-title":"Leukemia"},{"issue":"3","key":"837_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/ajh.20903","volume":"83","author":"WG Zhang","year":"2008","unstructured":"Zhang WG, Wang FX, Chen YX, et al. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia. Am J Hematol. 2008;83(3):185\u20138.","journal-title":"Am J Hematol"},{"issue":"11","key":"837_CR24","first-page":"1189","volume":"6","author":"E Feldman","year":"1992","unstructured":"Feldman E, Arlin Z, Ahmed T, et al. Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia. Leukemia. 1992;6(11):1189\u201391.","journal-title":"Leukemia"},{"issue":"2","key":"837_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/mpo.1177","volume":"37","author":"BA Bell","year":"2001","unstructured":"Bell BA, Chang MN, Weinstein HJ. A phase II study of homoharringtonine for the treatment of children with refractory or recurrent acute myelogenous leukemia: a pediatric oncology group study. Med Pediatr Oncol. 2001;37(2):103\u20137.","journal-title":"Med Pediatr Oncol"},{"key":"837_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1756-8722-2-32","volume":"2","author":"J Wang","year":"2009","unstructured":"Wang J, L\u00fc S, Yang J, et al. A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China. J Hematol Oncol. 2009;2:32\u20136.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"837_CR27","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1158\/1535-7163.MCT-05-0164","volume":"5","author":"R Tang","year":"2006","unstructured":"Tang R, Faussat AM, Majdak P, et al. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther. 2006;5(3):723\u201331.","journal-title":"Mol Cancer Ther"},{"key":"837_CR28","first-page":"27","volume":"125","author":"C Picard","year":"2006","unstructured":"Picard C, Silvy M, Gabert J. Overview of real-time RT-PCR strategies for quantification of gene rearrangements in the myeloid malignancies. Methods Mol Med. 2006;125:27\u201368.","journal-title":"Methods Mol Med"},{"issue":"24","key":"837_CR29","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky K, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642\u20139.","journal-title":"J Clin Oncol"},{"issue":"6","key":"837_CR30","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1086\/339215","volume":"34","author":"WT Hughes","year":"2002","unstructured":"Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34(6):730\u201351.","journal-title":"Clin Infect Dis"},{"issue":"71","key":"837_CR31","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1021\/jo00951a040","volume":"38","author":"WW Paudler","year":"1973","unstructured":"Paudler WW, McKay J. The structures of some of the minor alkaloids of Cephalotaxus fortunei. J Org Chem. 1973;38(71):2110\u20132.","journal-title":"J Org Chem"},{"key":"837_CR32","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0040-4039(01)97839-6","volume":"11","author":"RG Powell","year":"1970","unstructured":"Powell RG, Weisleder D, Smith CR Jr, et al. Structures of harringtonine, isoharringtonine, and homoharringtonine. Tetrahedron Lett. 1970;11:815\u20138.","journal-title":"Tetrahedron Lett"},{"key":"837_CR33","unstructured":"Mei W-L, Wu J, Dai H-F. Advances in studies on chemical constituents in plants of Cephalotaxus Sieb, Et Zucc. and their pharmacological activities. Chin Tradit Herb Drugs 2006;37(3):452\u20138."},{"issue":"6","key":"837_CR34","first-page":"487","volume":"118","author":"M Wen-Yuan","year":"2005","unstructured":"Wen-Yuan M, Mao-Fang L. Induction of apoptosis by homoharringtonine in G1 phase human chronic myeloid leukemic cells. Chin Med J (Engl). 2005;118(6):487\u201392.","journal-title":"Chin Med J (Engl)"},{"issue":"9","key":"837_CR35","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood.V86.9.3322.bloodjournal8693322","volume":"86","author":"S O\u2019Brien","year":"1995","unstructured":"O\u2019Brien S, Kantarjian H, Keating M, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood. 1995;86(9):3322\u20136.","journal-title":"Blood"},{"issue":"12","key":"837_CR36","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1182\/blood.V93.12.4149","volume":"93","author":"S O\u2019Brien","year":"1999","unstructured":"O\u2019Brien S, Kantarjian H, Koller C, et al. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood. 1999;93(12):4149\u201353.","journal-title":"Blood"},{"issue":"5","key":"837_CR37","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/cncr.11620","volume":"98","author":"S O\u2019Brien","year":"2003","unstructured":"O\u2019Brien S, Giles F, Talpaz M, et al. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer. 2003;98(5):888\u201393.","journal-title":"Cancer"},{"issue":"1","key":"837_CR38","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/mpo.10264","volume":"41","author":"J Tang","year":"2003","unstructured":"Tang J, Xue H, Pan C, et al. A homoharringtonine-based regimen for childhood acute myelogenous leukemia. Med Pediatr Oncol. 2003;41(1):70\u20132.","journal-title":"Med Pediatr Oncol"},{"key":"837_CR39","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1200\/JCO.2004.01.191","volume":"22","author":"U Creutzig","year":"2004","unstructured":"Creutzig U, Zimmermann M, Reinhardt D, et al. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol. 2004;22:4384\u201393.","journal-title":"J Clin Oncol"},{"issue":"2","key":"837_CR40","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1046\/j.1365-2141.1999.01550.x","volume":"106","author":"LC Riley","year":"1999","unstructured":"Riley LC, Hann IM, Wheatley K, et al. Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council Acute Myeloid Leukaemia Trial (MRCAML10). The MCR Childhood Leukaemia Working Party. Br J Haematol. 1999;106(2):436\u201344.","journal-title":"Br J Haematol"},{"issue":"11","key":"837_CR41","first-page":"1185","volume":"6","author":"E Feldman","year":"1992","unstructured":"Feldman E, Arlin Z, Ahmed T, et al. Homoharringtonine is safe and effective for patients with acute myelogenous leukemia. Leukemia. 1992;6(11):1185\u20138.","journal-title":"Leukemia"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-011-0837-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-011-0837-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-011-0837-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-011-0837-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T11:37:18Z","timestamp":1592480238000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-011-0837-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,21]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["837"],"URL":"https:\/\/doi.org\/10.1007\/s12185-011-0837-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,21]]}}}